A double blind randomised control trial investigating the efficacy of platelet rich plasma versus placebo for the treatment of greater trochanteric pain syndrome (the HIPPO trial): a protocol for a randomised clinical trial

Eshan Oderuth¹, Mohammed Ali²*, Ismael Atchia²† and Ajay Malviya²†

Abstract

Background: Greater trochanteric pain syndrome (GTPS) is a painful condition characterised by pain around the greater trochanter usually affecting middle-aged women. The majority of patients will improve with conservative management such as physiotherapy and non-steroidal anti-inflammatory drugs (NSAIDs); however, if this fails then more invasive treatments including corticosteroid injections and surgery may be required. Platelet-rich plasma (PRP) is an autologous blood product, which has a higher concentration of growth factors postulated to provide enhanced healing and anti-inflammatory properties. There have been numerous studies on PRP’s efficacy in musculoskeletal soft tissue conditions with similar pathology to GTPS, with varying results, most promising being in plantar fasciopathy and patellar tendinopathy. Corticosteroids are the established second-line treatment, but do not always work long term. PRP may be a suitable alternative to corticosteroid in GTPS with longer-term effects; however, there are very limited reports. The Hip Injections PRP Vs Placebo (HIPPO) trial aims to assess the ability of PRP to improve symptoms and function in patients with GTPS.

Methods/design: HIPPO is a single-centre, double-blind randomized placebo-controlled study in patients with a radiologically confirmed diagnosis of gluteus medius or minimus tendinopathy with swelling within the tendon insertion with or without bursitis. We aim to randomise 102 patients with GTPS to either the PRP or placebo (normal saline injection) treatment arm. Participants will receive one ultrasound (US) guided PRP/placebo injection into the trochanteric bursa and surrounding gluteus medius/minimus tendons. The primary outcome measure is the International Hip Outcome Tool-12. Secondary outcome measures will include a visual analogue score for pain, the three-level version of the EuroQol five-dimensional questionnaire and the modified Harris Hip Score. Outcomes will be measured at baseline, 3, 6 and 12 months. Participants will have the option at 6 months to have a repeat blinded injection or cross over to PRP. Analyses of primary and secondary outcomes will be made according to the intention-to-treat principle. The trial reporting will comply with Consolidated Standards of Reporting Trials (CONSORT) guidelines.

(Continued on next page)
Background

Overview

Greater trochanteric pain syndrome (GTPS), also known as trochanteric bursitis, can be a debilitating condition characterised by pain around the greater trochanter. Pain increases on walking, squatting or climbing stairs and when lying on the affected side or when crossing one’s legs [1–3]. GTPS was a term adopted by Karpinski et al. in 1985 instead of trochanteric bursitis as patients did not exhibit typical bursitis signs of swelling, heat, crepitus or fluctuation [4]. This notion has been supported by other studies [5] including a study performed by Bird et al. 2001. They evaluated 24 patients using magnetic resonance imaging with the clinical picture of GTPS and found that the majority of patients had gluteus medius tendon pathology with only 2 patients with isolated trochanteric bursal inflammation [1]. Hence, GTPS instead of trochanteric bursitis appears to be the more accurate way of describing the clinical condition, which clearly may have multiple facets in its pathology.

A selection of non-surgical management options is normally recommended, including rest, ice, stretching, heat, strengthening and oral anti-inflammatory drugs. The majority of patients improve with conservative management; however, if this fails then more invasive treatment options may be explored, including shockwave therapy, corticosteroid injections [6–8] and even surgery. Corticosteroid injection is an established second-line treatment for GTPS that has been shown to be efficacious but not necessarily in the long term, as reported by previously published studies [9]. This notion has been supported by numerous reviews of GTPS management [10–12]. Surgery is usually set aside until the condition has become refractory and conservative measures have been exhausted. Reports of PRP use as a novel therapy in GTPS are very limited. A review of treatments for GTPS by Buono et al. stated the following: “as platelet rich plasma (PRP) has been widely used to stimulate biological tendon healing in patients with chronic tendinopathies, futures trends of research and trials should focus on the application and effectiveness of PRP for the management of GTPS” [11].

Existing knowledge

PRP is an autologous blood product, which has been postulated to promote healing in damaged or inflamed tissues including muscles, ligaments, bones and tendons. Platelets contain a variety of elements including growth factors and cytokines, which are involved in tissue healing. These include, platelet-derived endothelial growth factor (PD-EGF), platelet-derived growth factor (PDGF), transforming growth factor (TGF), insulin-like growth factor (IGF), vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF). These growth factors are present in the processes of tissue injury, inflammation and repair. Therefore, theoretically the higher the concentration of platelets, the more growth factors there will be present to promote the healing process when administered directly to the area of interest [13].

PRP has been applied in other fields of medicine including regenerative therapies in oral and maxillofacial surgery [14, 15] Over the past decade or so there have been numerous studies of the efficacy of PRP in treating musculoskeletal conditions similar in pathology to GTPS, such as lateral epicondylitis, patellar tendinitis, rotator cuff pathology, Achilles tendinopathy and plantar fasciopathy. This has been collectively reviewed by several authors with reports of mixed efficacy compared to standard treatments for these conditions with the most promise shown in plantar fasciopathy and patellar tendinitis [16–18]. These reviews all mention the lack of evidence to fully support or reject the efficacy of PRP in these conditions, except for Achilles tendinopathy where PRP showed no difference compared with placebo in a randomised study [19, 20]. The healing or regenerative properties of PRP have shown promise in other orthopaedic areas such as cartilage pathology [21].

Aims

The aim of the trial is to investigate the clinical efficacy of the novel treatment platelet-rich plasma (PRP) in treating patients with GTPS. The clinical efficacy of PRP will be compared against a placebo injection of normal saline.

Hypothesis

PRP is an effective treatment for greater trochanteric pain syndrome.

The need for the trial

GTPS can be a painful and debilitating condition, which as a last resort requires surgery especially if it does not
respond to conservative treatment. This is clearly a developing field with a lack of published research with on-going studies investigating the efficacy of PRP in GTPS. Our trial differs from the other trials in its design as we will compare PRP with placebo. Our aim is to conduct a well-designed robust trial to establish whether PRP is effective compared to placebo and what the duration of the effect is for patients suffering from GTPS.

Methods
Trial design
The trial will be a two-arm, single-centre, double-blind, randomised control trial (RCT). The study will include a two-way comparison between PRP and placebo normal saline injections for treating GTPS. The trial design has been based on our local experience with using PRP in patients with GTPS and an RCT conducted by Monto et al. in 2014 [22] comparing steroid injection with PRP in patients with severe hip bursitis. Add to this, a pilot study by Ribeiro et al. in 2016 [23], which compared the efficacy of PRP against corticosteroid in the treatment of GTPS.

Participants will be identified and referred for inclusion in the study by their main care provider (general practitioner (GP), orthopaedic surgeon, rheumatologist or extended-scope practitioner). They will then be invited for a first interview where eligibility will be assessed, further information about the study will be given and written consent for inclusion obtained. Potential participants will be permitted to reschedule another interview appointment if they need more time to think about whether they wish to participate. Participants will be allocated randomly to either the PRP or normal saline injection treatment arm. They will receive their treatment under sterile conditions under ultrasound guidance by a consultant rheumatologist (IA). The participant will be contacted by phone a week after receiving treatment to monitor for early adverse events. Participants and outcome assessors will be blinded to treatment arm. Participants will be reviewed at baseline, 3, 6 and 12 months with patient-reported outcome measures (PROM) completed at each of these reviews. During the 6 months follow up participants will be given the option of a repeat injection of their original treatment or if they specifically request PRP then we will offer this to them but maintain the blinding of their original treatment. This was a key ethical discussion point in our focus group meeting engaging patient and public involvement in that expecting the blinding of their original treatment. This was a key ethical discussion point in our focus group meeting engaging patient and public involvement in that expecting the blinding of their original treatment. This was a key ethical discussion point in our focus group meeting engaging patient and public involvement in that expecting the blinding of their original treatment. This was a key ethical discussion point in our focus group meeting engaging patient and public involvement in that expecting the blinding of their original treatment. This was a key ethical discussion point in our focus group meeting engaging patient and public involvement in that expecting the blinding of their original treatment. This was a key ethical discussion point in our focus group meeting engaging patient and public involvement in that expecting the blinding of their original treatment. This was a key ethical discussion point in our focus group meeting engaging patient and public involvement in that expecting the blinding of their original treatment. This was a key ethical discussion point in our focus group meeting engaging patient and public involvement in that expecting the blinding of their original treatment. This was a key ethical discussion point in our focus group meeting engaging patient and public involvement in that expecting the blinding of their original treatment. This was a key ethical discussion point in our focus group meeting engaging patient and public involvement in that expecting the blinding of their original treatment. This was a key ethical discussion point in our focus group meeting engaging patient and public involvement in that expecting the blinding of their original treatment. This was a key ethical discussion point in our focus group meeting engaging patient and public involvement in that expecting the blinding of their original treatment. This was a key ethical discussion point in our focus group meeting engaging patient and public involvement in that expecting the blinding of their original treatment. This was a key ethical discussion point in our focus group meeting engaging patient and public involvement in that expecting the blinding of their original treatment. This was a key ethical discussion point in our focus group meeting engaging patient and public involvement in that expecting the blinding of their original treatment. This was a key ethical discussion point in our focus group meeting engaging patient and public involvement in that expecting the blinding of their original treatment. This was a key ethical discussion point in our focus group meeting engaging patient and public involvement in that expecting the blinding of their original treatment. This was a key ethical discussion point in our focus group meeting engaging patient and public involvement in that expecting the blinding of their original treatment. This was a key ethical discussion point in our focus group meeting engaging patient and public involvement in that expecting the blinding of their original treatment. This was a key ethical discussion point in our focus group meeting engaging patient and public involvement in that expecting the blinding of their original treatment.

Recruitment
The source of recruitment will be from their main care provider (GP, orthopaedic surgeon, rheumatologist or extended-scope practitioner). Following the first interview and consent to enter the trial, eligibility checks (Table 1) will be repeated for each participant on the day they attend for treatment, to ensure that participants are not randomised in error. The participant will receive confirmation of their inclusion in the trial, which will also be recorded in their medical notes. Their GP will be informed.

### Table 1 Inclusion and exclusion criteria

| Inclusion criteria:                                      |
|--------------------------------------------------------|
| Over 18 years of age                                    |
| Symptoms consistent with GTPS present for at least 6 months |
| Radiological diagnosis of GTPS using MRI, or ultrasound scan if MRI contraindicated |
| Failed conservative management in any other care setting |
| Patient is willing and able to provide written informed consent |

| Exclusion criteria:                                     |
|-------------------------------------------------------|
| Lacks capacity to provide consent                      |
| Has hip joint osteoarthritis demonstrated on a plain radiograph, requiring treatment |
| Presence of confounding pathologies on the hip MRI     |
| Any extensive surgery or deformity of the hip demonstrated on x-ray |
| Presence of systemic disorders – coagulopathy, active infection, immune system disorders, peripheral neuropathy, malignancy, unresolved fractures |
| Had any surgical treatment specifically targeted at GTPS e.g. bursectomy/ilio-tibial band lengthening |
| Pregnancy                                              |
| Anti-coagulant therapy e.g. warfarin, rivaroxaban, apixaban, dabigatran |
| Haemoglobin < 10 g/dl or platelets < 150,000/ul        |
| Unable to safely stop anti-platelet/NSAID medications e.g. recent cardiac stenting |
| Has lumbar-sacral spine pathology or a recent history of acute hip trauma |
| Has a recent history of acute sciatica                  |
| Is not able to attend or comply with treatment or follow up scheduling |
| Participates in any other clinical trial                |

The feasibility and scientific quality of the trial has been peer-reviewed and approved by the Principal Investigator (PI) and Research and Development team. The ethical approval was granted by Health Research Authority (HRA) England and the trial is listed with the number 198415. The trial protocol will permit its reporting in line with the Consolidated Standards of Reporting Trials (CONSORT) guidelines [24]. [The Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) checklist is provided as Additional file 1].
Consent
All potential participants will attend a first interview meeting with our research team following referral from their primary care provider (e.g. GP/orthopaedic surgeon/rheumatologist). They should already have received the trial information sheet. We will explain the purpose and nature of the trial again and assess their eligibility. They will be given up to a week to decide whether they wish to be entered into the trial. A second interview will be rescheduled if necessary. Written consent to enter the trial will be obtained. Once the participant has consented, their baseline PROMs will be assessed and recorded.

Treatment allocation
Sequence generation
The allocation sequence will be generated randomly using an online computer-generated randomiser (https://sealedenvelope.com/). The participant will be allocated to either the PRP or normal saline arm of the trial. All injections will be performed by the same consultant rheumatologist who will be not involved in the data collection process.

Allocation concealment
The allocation sequence will be hidden from the PI and outcome assessors. Their allocation will be recorded on a separate database to which the PI/outcome assessors will not have access. Only the treatment administrator (consultant rheumatologist) will have access to this so they know what treatment they are issuing. They and a dedicated research nurse will be guardians of this allocation sequence database to ensure that the patients, PI and outcomes assessors do not have access. Allocation will be revealed once the trial has ended and data analysis begins.

Allocation implementation
Participants will be enrolled by our research team lead by the PI (AM). They will have been allocated their treatment randomly. Allocations will be held on a secure database which the treatment administrator (consultant rheumatologist (IA)) will have access on the day of their treatment.

Blinding
All participants will be blinded to the treatment allocation. All treatments will be prepared in another room and the patient will have a screen between them and their hip preventing them from seeing what treatment they are being given. The treatment administrator will not be blinded. Outcome assessors will be blinded.

Trial treatments
All participants will attend the hospital as a day case. As per Northumbria Healthcare NHS Foundation Trust policies, written consent will be obtained for their procedure, which will be generic to cover both treatment arms. All participants will have 40 ml of blood drawn using an aseptic technique, which will then be taken to another room for 20 min to simulate the centrifuge time for the PRP preparation, regardless of which treatment they are receiving. They will also have a drape obscuring their hip and treatment area from their line of sight. All these measures are to maintain blinding of the participant to treatment allocation. The procedure will take place in sterile conditions to minimise the risk of infection. They will have local anaesthetic infiltrated superficially and deep in the greater trochanteric area. Our consultant rheumatologist will then inject either PRP or normal saline under ultrasound guidance into the trochanteric bursa and abductor tendons (2 ml in the abnormal tendon and 2 ml in the bursa). All participants will then be advised to rest for 72 h and will be referred for physiotherapy.

Participants will be randomised into 2 groups:
1. Test: PRP treatment using the SW-PRP system provided by NTL Biologica – 40 ml of the participant’s own blood is added to 6 ml of ACD-A (Anticoagulant Citrate Dextrose Solution, Solution A). This is then placed into the SW-PRP Syringe Device. The vial is centrifuged at 3850 rpm for 7 min. Red blood cell fluid level in the device is optimised and then centrifuged for a further 4 min at 3850 rpm. Platelet-poor plasma is extracted from the device and discarded. The remaining PRP is extracted from the buffy coat layer; 4 ml of PRP is withdrawn and is ready for administration.
2. Placebo: 4 ml of normal 0.9% saline.

Physiotherapy
The physiotherapy protocol will include stretching exercises, which consist of gluteal, iliobibial band and piriformis stretching. Prone lumbar extension, supine lumbar rotation and cat stretch exercises will also be included. These are accompanied with strengthening exercises such as side-lying leg lift, clam, gluteal kickback and balance exercises. This will be a general standardised physiotherapy regime and will be standardised across our physiotherapy requests. Naturally the physiotherapy that participants receive may vary, such as by the frequency of sessions, and we accept this as a variable that could influence outcome; however, measures will be taken to minimise this as much as possible.

Measure of harm and adverse events
Participants will be monitored for adverse events at each follow up. One week after their treatment each
participant will receive a phone call to monitor early adverse events. Adverse events will be reported in the study publication.

Expected potential adverse events:

- Pain
- Infection
- Failure to relieve/recurrence/progression of symptoms/exacerbation

**Outcome measures**

**Primary**
The International Hip Outcome Tool–12 (iHOT-12) PROM scores at baseline, 3, 6 and 12 months will be compared within and between the PRP and normal saline arms.

**Secondary**
The visual analogue score (VAS) for pain, the Modified Harris Hip Score (mHHS) and the three-level version of the EuroQol five-dimensional (EQ-5D 3 L) questionnaire PROM scores will be collected at baseline, 3, 6 and 12 months and will be compared within and between the PRP and normal saline arms (Fig. 1).

**End of the trial**
Recruitment will cease once the last participant has been recruited following our sample size recommendations. The trial will cease once the last patient has attended their 12 months follow up (Fig. 2).

**Data management**
The data collected from the trial will be entered into a trial database. The database will be agreed and set up by our information technology (IT) technician, statistician and PI. The database will be stored securely on our computer systems in the hospital. During the interim analysis, the database will be frozen to ensure data collected after this point are not included in the interim report. Access to the data will be limited to those only directly involved in the trial and who are part of the research team. The data will be anonymised in terms of participant identifiable data and will only contain demographic details. Identifiable participant data will be held on a separate database in our secure computer network in the hospital. Each participant will have a unique participant code so their outcome data can be matched with their personal identifiable data if required. All physical data will be stored in the Research and Development Office, North Tyneside General Hospital in a locked cabinet. The office is secured by a code-operated lock and is only accessible by the research team. All computer data will be stored on our secure password-protected National Health Service (NHS) Trust computers. Data will be archived in accordance with the Research and Development Department, Northumbria Healthcare NHS Foundation Trust guidance. A data monitoring committee will be formed and will convene for this trial.

**Data Monitoring Committee**
A Data Monitoring Committee will convene at the interim period of 50% recruitment at 6-month follow up. This will be chaired by the PI and include other co-investigators, a trial coordinator and ideally a member of our patient focus group. All issues relating to the management and conduct of the trial will be reviewed and addressed. Meeting times will be an interim meeting at 50% recruitment reaching 6-month follow up and the end of trial.

**Statistical analysis**

**Statistician report**
The primary outcome of interest is the change from baseline to 12-month follow up in the iHOT-12, comparing the PRP and placebo group. The study will be run as a superiority trial. The cut-off for statistical significance is set at 5% and desired power at 90%, with two-tailed tests applied. Data on change from baseline are also assumed to be parametric and the t test will be applied to the data to assess statistical significance.

The minimally clinically important difference (MCID) for the iHOT-12 has been reported by Sansone et al. as 10 (from 100) and the standard deviation for the change in score from baseline as no greater than 21 [25]. Although, there are few previous data on which to base a sample size calculation, Monto et al. compared change from baseline to 12-month follow up in a group of 40 patient with hip bursitis, with steroids and PRP as the interventions being compared. In the PRP group Harris Hip scores increased from 51.7 to 87.4 whilst in the steroid group, scores increased from 50.5 to 58.8 at 12 months [22]. Since the Harris Hip score is also scored from 100, our sample size calculation is based on these figures. We conservatively assume that change in iHOT score from baseline in the placebo group will be no more than in the steroid group reported by Monto et al., and estimate a maximal change of 10. We also estimate that the change in the iHOT score from baseline in the PRP group will be no less than 27. Using these figures, a minimal sample size at follow up of 66 (33 in each group) will be required.

Pilot data obtained by our team suggest that the rate of refusal to participate should be no more than 25% and the dropout rate no more than 35% over 12 months. Refusal rates tend to be low in this patient group given the chronic nature of the condition and the fact that patients will only be approached once conservative management has failed. Thus, we will need to approach
135.4 (rounded up to 136) patients, and recruit 102 patients to achieve our target sample size.

Data will be analysed using standard statistical software (e.g. SPSS and SAS). In the first instance, data will be analysed using simple descriptive statistics to compare the two groups in terms of demographics, clinical characteristics at baseline and outcomes. The primary outcome of interest will be the change from baseline to 12-month follow up in the iHOT-12, comparing the PRP and placebo group. The iHOT-12 data are expected to be parametric and so the unpaired t test will be used to compare the difference in change from baseline in the
two groups. Since randomisation will not be stratified,
we will also look to adjust for the possible confounding
influence of differences in baseline characteristics (e.g.
age, gender and body mass index (BMI)) using multivari-
able methods (e.g. linear regression). The significance
level for all inferential tests will be set at 5%.

In secondary analysis, we will investigate changes in
visual analogue pain score, EQ-5D 3 L and modified
Harris Hip score in the two groups, as for the primary
outcome. In sub-group analysis, we will investigate the
data based on specific previous treatment, patients who
required more than one treatment and patients with the
highest levels of baseline pain.

The test group (PRP) alone: for all outcome measures
the difference between the follow up scores with base-
line will be assessed (e.g. baseline versus 3 months,
baseline versus 12 months). The difference between
one follow up period to the next will be examined (e.g.
3 months versus 6 months, 6 months versus 12 months).
A significant difference will be set at a \( p \) value of less
than 0.05.

The placebo group (normal saline) alone: data will be
analysed as for the test group, as described.

Test versus placebo: for all outcome measures, the dif-
ferential change at each follow up time point will be
compared between the trial arms and the significance
value calculated.

Statistical tests will be performed to ensure that gen-
der, BMI and age differences are not significantly associ-
ated with a particular result. Care will be taken to
minimise missing responses and to continue to follow
up those who withdraw from treatment.

We will only be using the completed cases for final
analyses; the remainder will be excluded.

**Discussion**

Platelet-rich plasma (PRP) is an autologous blood product,
which has a higher concentration of growth factors postu-
lated to provide enhanced healing and anti-inflammatory
properties. There have been numerous studies on the effi-
cacy of PRP in musculoskeletal soft tissue conditions with
similar pathology to GTPS, with varying results, the most
promising being in plantar fasciopathy and patellar tendi-
nopathy. Corticosteroids are the established second-line
treatment, but do not always work long term. PRP may be
a suitable alternative to corticosteroid in GTPS, with
longer-term effects; however, there are very few reports
discussing its efficacy. Lee et al. in 2016 [26] prospectively
studied the efficacy of intra-tendinous PRP injections as
treatment for chronic recalcitrant gluteus medius tendino-
pathy. They found ultrasound-guided intra-tendinous PRP
injections to be a safe and effective treatment option for
chronic recalcitrant gluteus medius tendinopathy due to
moderate to severe tendinosis. A second report by
Ribeiro et al. from Brazil [23] was published in 2016
comparing the efficacy of PRP against corticosteroids.
They concluded that during the first 2 months, which
was the study period, the PRP has no influence on pain
relief and functional improvement in trochanteric syn-
drome. Again in 2016 a third report from the USA
compared ultrasound-guided percutaneous tendon fen-
estration to PRP injection for treatment of GTPS [27].
The report concluded that both ultrasound-guided ten-
don fenestration and PRP injection are effective for
treatment of gluteal tendinosis, showing symptom im-
provement in both treatment groups. Large effect sizes
were evident in these studies. We calculated these based
on Cohen’s test, taking some statistical assumptions into
account, given that all data were not available. The effect
senses in the study of Lee et al. were 1.303, 1.052, 0.883 and 1.677 for the mHHS, Hip Outcome Score (HOS) activities of daily living, HOS sport and HOT-33, respectively. The effect sizes in the study of Ribeiro et al. were 1.155, 1.371 and 1.509 for the Facial Expressions Scale for Pain at follow-up of 10, 30 and 60 days.

Prior to these reports, Mautner et al. conducted a study in 2013 [28] to assess whether ultrasound-guided PRP injections are an effective treatment for chronic tendinopathies. The study included 180 patients of whom 16 had gluteus medius tendinopathy. The majority experienced significant improvement in symptoms, evidenced by 82% of patients reporting at least moderate improvement of their symptoms. A similar satisfaction rate of 85% was also found, respectively, demonstrating that the improvement in symptoms likely resulted in patient satisfaction. There are no randomised trials in the current literature and all these published reports were based on short follow-up periods and small numbers of patients.

This paper describes the rationale and design for the first randomised trial that aims to determine the effectiveness of PRP in the treatment of greater trochanteric pain syndrome. No previous trials have assessed PRP against placebo or measured clinical outcomes beyond 6 months. The HIPPO trial will make a significant contribution to the evidence base available to support effective conservative management of GTPS.

Current status of the trial
The trial is currently running. Recruitment and treatment started in spring 2018.

Additional file

**Additional file 1**: Standard protocol items: recommendation for Interventional trials (SPIRIT) 2013 checklist. Recommended items to address in a clinical trial protocol and related documents. (DOC 121 kb)

Abbreviations

BfGF: Basic fibroblast growth factor; BMI: Body mass index; CONSORT: Consolidated Standards of Reporting Trials; EQ-SD: 3 L: Three-level version of the EuroQol five-dimensional questionnaire; GP: General practitioner; GTPS: Greater trochanteric pain syndrome; IgF: Insulin-like growth factor; iHOT-12: International Hip Outcome Tool-12; mHHS: Modified Harris Hip Score; NHS: National Health Service; NSAID: Non-steroidal anti-inflammatory drug; PD-EGF: Platelet-derived endothelial growth factor; PDGF: Platelet-derived growth factor; PI: Principal Investigator; PROM: Patient-reported outcome measures; PRP: Platelet-rich plasma; RCT: Randomised control trial; TGF: Transforming growth factor; VAS: Visual analogue score for pain; VEGF: Vascular endothelial growth factor

Acknowledgements

We are grateful to all the clinical, research and administrative staff involved in the set-up of the trial and recruitment of participants, including Deborah Bunn, Chris Herriott, Gail Waddell and Rachel Browell. We would like to thank the NTU Biologica team who are going to provide the PRP kit for the study and support the injection clinics. We are also grateful to Dr Louise Hayes and National Institute for Health Research (NIHR) RDS North East for all help and support, and we would like to thank all the members of this group.

Funding

Provision of a centrifuge and PRP kits have been secured from NTU Biologica. Funding support was from the Research and Development Office, North Tyneside General Hospital.

Authors’ contributions

EO, MA, IA and AM all contributed to the overall design of the study and manuscript preparation, and read and approved it for final submission.

Ethics approval and consent to participate

The trial received full ethical approval from Health Research Authority England on 23 October 2017, registration number 198415. The study was also approved by Northumbria Healthcare NHS Foundation Trust. Any modifications to the protocol will be submitted for further ethical approval and approved changes will be documented on the ClinicalTrials.gov registry. The trial will be conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki, 1966; the principles of Good Clinical Practice, and the Department of Health Research Governance Framework for Health and Social Care, 2005.

Written informed consent will be obtained from all participants in the trial. Copies of the consent forms will be kept in the trial site files and the patients’ medical notes. Participants will be free to withdraw from the study at any time without giving a reason. All the information collected during this trial will be confidential and held in accordance with NHS Data Protection guidelines and Good Clinical Practice guidelines. Confidentiality will only be breached if patients disclose to us information that may indicate that there is a risk of harm to themselves or others.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1Chesterfield Royal Hospital, Chesterfield, UK. 2Northumbria Healthcare NHS Foundation Trust, North Shields, UK.

Received: 9 April 2018 Accepted: 7 September 2018

Published online: 21 September 2018

References

1. Bird PA, Oakley SP, Shinier R, et al. Prospective evaluation of magnetic resonance imaging and physical examination findings in patients with greater trochanteric pain syndrome. Arthritis Rheum. 2001;44:2138–45.
2. Anderson TP. Trochanteric bursitis: diagnostic criteria and clinical significance. Arch Phys Med Rehabil. 1958;39:617–22.
3. Little H. Trochanteric bursitis: a common cause of pelvic girdle pain. Can Med Assoc J. 1979;120(4):456–8.
4. Karpinski MR, Piggott H. Greater trochanteric pain syndrome. A report of 15 cases. J Bone Joint Surg Br. 1985;67(5):762–3.
5. Silva F, Adams T, Feinstein J, Arroyo RA. Trochanteric bursitis: refuting the myth of in animation. J Clin Rheumatol. 2008;14(2):82–6.
6. Lustenberger DP, Ng VY, Best TM, et al. Efficacy of treatment of trochanteric bursitis: a systematic review. Clin J Sport Med. 2011;21:447–53.
7. Mulligan EP, Middleton EF, Brunette M. Evaluation and management of greater trochanter pain syndrome. Phys Ther Sport. 2015;16:205–204. https://doi.org/10.1016/j.ptsp.2014.11.002.
8. Redmond JM, Chen AW, Domb BG. Greater Trochanteric Pain Syndrome. J Am Acad Orthop Surg. 2016;24:231–40. https://doi.org/10.5435/JAAOS-D-14-00406.
9. Brinks A, van Rijn RM, Willemsen SP. Corticosteroid injections for greater trochanteric pain syndrome: a randomized controlled trial in primary care. Ann Fam Med. 2011;9:226–34.
10. Williams BS, Cohen SP. Greater trochanteric pain syndrome: a review of anatomy, diagnosis and treatment. Anesth Analg. 2009;108:1662–70.
11. Del Buono A, Papalia R, Khanduja V, et al. Management of the greater trochanteric pain syndrome: a systematic review. Br Med Bull. 2012;102:115–31.
12. Chowdhury R, Naaseri S, Lee J, et al. Imaging and management of greater trochanteric pain syndrome. Postgrad Med J. 2014;90:576–81.
13. Foster TE, Puiskas BL, Mandelbaum BR, Gerhardt MB, Rodeo SA. Platelet-rich plasma: from basic science to clinical applications. Am J Sports Med. 2009; 37(11):2259–72.
14. Del Corso M, Vervelle A, Simonpieri A, et al. Current knowledge and perspectives for the use of platelet-rich plasma (PRP) and platelet-rich fibrin (PRF) in oral and maxillofacial surgery part 1: periodontal and dentoalveolar surgery. Curr Pharm Biotechnol. 2012;13:1207–30.
15. Simonpieri A, Del Corso M, Vervelle A, et al. Current knowledge and perspectives for the use of platelet-rich plasma (PRP) and platelet-rich fibrin (PRF) in oral and maxillofacial surgery part 2: bone graft, implant and reconstructive surgery. Curr Pharm Biotechnol. 2012;13:1231–56.
16. Liddle AD, Rodríguez-Merchán EC. platelet-rich plasma in the treatment of patellar tendinopathy: a systematic review. Am J Sports Med. 2015;43:2583. https://doi.org/10.1177/0363546514560726.
17. Moraes VY, Lenza M, Tamaoki MJ, Faloppa F, Belloti JC. Platelet-rich therapies for musculoskeletal soft tissue injuries. Cochrane Database Syst Rev. 2014;(Issue 4)Art. No.: CD010071. https://doi.org/10.1002/14651858.CD010071.pub3.
18. Franceschi F, Papalia R, Franceschetti E, Pacotti M, Maffulli N, Denaro V. Platelet-rich plasma injections for chronic plantar fasciopathy: a systematic review. Br Med Bull. 2014;112:83–95. https://doi.org/10.1093/bmb/ldu025.
19. Maffulli N, Longo UG, Lopinni M, et al. Current treatment options for tendinopathy. Expert Opin Pharmacother. 2010;11:2177–86.
20. de Vos RJ, Weir A, van Schie HT, Biema-Zeinstra SM, Verhaar JA, Weinans H, et al. Platelet-rich plasma injection for chronic Achilles tendinopathy. JAMA. 2010;303(2):144–9.
21. Marmotti A, Rossi R, Castoldi F, Roveda E, Michielon G and Peretti GM. PRP and articular cartilage: a clinical update. Biomed Res Int. Volume 2015, Article ID 542502, 19 pages. https://doi.org/10.1155/2015/542502
22. Monto RR. Paper #778. Presented at: American Academy of Orthopaedic Surgeons Annual Meeting. New Orleans; 2014. http://aaos2014.conferencespot.org/author-index.
23. Ribeiro AG, Junior RW, Silva AR, Polesello GC, Guimaraes RP. PRP in the treatment of trochanteric syndrome: a pilot study. Acta Ortop Bras. 2016; 24(4):208–12.
24. Altman DG. Better reporting of randomised controlled trials: the CONSORT statement. BMJ. 1996;313(7057):570–1.
25. Sansone M, Ahlden M, Jonasson P, et al. Outcome of hip arthroscopy in patients with mild to moderate osteoarthritis—a prospective study. J Hip Preserv Surg. 3(1):61–7. https://doi.org/10.1093/jhps/hmw079.
26. Lee JJ, Harrison JR, Boachie-Adjei K, Vargas E, Moley PJ. Platelet-rich plasma injections with needle tenotomy for gluteus medius tendinopathy: a registry study with prospective follow-up. Orthop J Sports Med. 2016;4(11):232596716671692.
27. Jacobson JA, Yablons CM, Henning PT, Kazmers IS, Urquhart A, Hallstrom B, Bedi A, Parameswaran A. Greater trochanteric pain syndrome: percutaneous tendon fenestration versus platelet-rich plasma injection for treatment of gluteal tendinosis. J Ultrasound Med. 2016;35(11):2413–20.
28. Mautner K, Colberg RE, Malanga G, Borg-Stein JP, Harmon KG, Dhararni AS, Chu S, Homer P. Outcomes after ultrasound-guided platelet-rich plasma injections for chronic tendinopathy: a multicenter, retrospective review. PM R. 2013;5(3):169–75.